Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CHAT | P28329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27591792 | 0.68 | KDM1A (0.37) | NFE2L2MAOBCHAT | |
| SCHEMBL2822193 | 0.67 | — | — | |
| SCHEMBL15282079 | 0.66 | — | — | |
| SCHEMBL28014648 | 0.66 | MAOB (0.36) | MAOB | |
| SCHEMBL28221256 | 0.63 | KDM1A (0.43) | MAOBCHAT | |
| SCHEMBL9227469 | 0.63 | KDM1A (0.43) | MAOBCHAT | |
| SCHEMBL23493566 | 0.61 | ALDH1A1 (0.37) | — | |
| SCHEMBL5112549 | 0.61 | KDM1A (0.41) | NFE2L2MAOBCHAT | |
| SCHEMBL23493564 | 0.61 | ALDH1A1 (0.37) | — | |
| SCHEMBL7781550 | 0.61 | MAOB (0.38) | NFE2L2MAOBCHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8945420-B2 | Liquid crystal display and liquid crystalline medium | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20120307177-A1 | LIQUID CRYSTAL DISPLAY AND LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-06 | — | — | US | disclosed |
| EP-0733366-B1 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | DU PONT (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0324377-B1 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | DU PONT (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0733366-A2 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0479903-B1 | SUBSTITUTED IMIDAZOLES USEFUL AS ANGIOTENSIN II BLOCKERS | DU PONT (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0253310-B1 | Angiotensin II receptor blocking imidazoles | DU PONT (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5354867-A | Hypertensive agents; congestive heart failure; used with diuretics to enhance activity; used with NSAIDs to prevent renal failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-10-11 | — | — | US | disclosed |
| US-5254546-A | Hypotensive agent | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0479892-A1 | FUSED-RING ARYL SUBSTITUTED IMIDAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-15 | — | — | EP | disclosed |
| EP-0479903-A1 | SUBSTITUTED IMIDAZOLES. | DU PONT (US) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991000277-A1 | SUBSTITUTED IMIDAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-10 | — | — | WO | disclosed |
| WO-1991000281-A2 | FUSED-RING ARYL SUBSTITUTED IMIDAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120307177-A1 | LIQUID CRYSTAL DISPLAY AND LIQUID CRYSTALLINE MEDIUM | CUTA, NEFM, FES | NFE2L2 3501/4885MAOB 212/4885CHAT 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.